source
- Bristol Myers unveils data for one of its next-gen blood cancer drugsCalled mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.BioPharma Dive · 2mo ago↗ source
- STAT+: Trump administration seeks to overhaul federal grantmaking process, alarming researchersThe Trump administration has released a sweeping proposal to overhaul the bedrock regulation for all federal grants.STAT · 2mo ago↗ source
- Replimune takes third swing at cancer drug approval following ‘productive’ FDA talksA twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.